Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement

The introduction of Bruton's tyrosine kinase (BTK) inhibitors transformed the management of patients with mantle cell lymphoma (MCL). Ibrutinib, the first-in-class BTK inhibitor is now approved in more than 80 countries and there are over 20 new BTK inhibitors in development. In addition, novel agents show potential clinical activity (alone and in combination) and are in the approval phase and/or being studied in ongoing clinical trials. How does the practicing clinician decide on the optimal therapeutic strategy for this highly heterogenous disease? In July 2020 a group of experts from Italy, convened a meeting to address and provide clarification on a series of outstanding issues in the treatment of MCL with the view of providing clinical guidance on its management. This expert opinion statement represents the panel's collective analysis, evaluation, and recommendations and is made up of a series of questions and answers (in the form of a review of the pertinent literature) designed to replicate those posed by practicing clinicians in Italy but which are applicable to clinical settings worldwide.

Automated summary

The introduction of BTK inhibitors has transformed the management of MCL patients, with ibrutinib being widely approved and many new inhibitors in development. Novel agents with potential clinical activity are also being studied in clinical trials. A group of experts convened a meeting to address outstanding issues and provide clinical guidance, resulting in an expert opinion statement with analysis, evaluation, and recommendations.